Phase 1 Atrial Fibrillation Trial, Recruiting (NCT06556732)

Phase 1 Atrial Fibrillation Trial, Recruiting NCT06556732 Sponsor: Assiut University Condition: Atrial Fibrillation

Printed from Voxsanity (voxsanity.com.au) — NCT06556732 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Atrial Fibrillation

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have atrial fibrillation (an irregular heartbeat) that is not caused by a heart valve problem, and your heart has been successfully returned to a normal rhythm — whether by medication, an electric shock treatment, or on its own.

Who may not be able to join:

You have rheumatic heart disease (heart damage caused by rheumatic fever).
You have a thyroid condition that is not working properly (either overactive or underactive).
You have a heart condition called Wolff-Parkinson-White (WPW) syndrome, which causes an abnormal electrical pathway in the heart.
You have kidney problems or reduced kidney function.
You have high levels of potassium in your blood (a condition called hyperkalemia).
You are currently experiencing or recently had a heart attack or severe chest pain episode (acute coronary syndrome).
You are pregnant.
Your heart's pumping strength is significantly reduced — specifically, if the main pumping chamber of your heart is working at less than 40% of its normal capacity.
You are currently taking a medication called eplerenone.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06556732

Sponsor: Assiut University

Phase: Phase 1

Status: Recruiting

Condition: Atrial Fibrillation

More information: https://clinicaltrials.gov/study/NCT06556732

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have atrial fibrillation (an irregular heartbeat) that is not caused by a heart valve problem, and your heart has been successfully returned to a normal rhythm — whether by medication, an electric shock treatment, or on its own.

Who may not be able to join:

You have rheumatic heart disease (heart damage caused by rheumatic fever).
You have a thyroid condition that is not working properly (either overactive or underactive).
You have a heart condition called Wolff-Parkinson-White (WPW) syndrome, which causes an abnormal electrical pathway in the heart.
You have kidney problems or reduced kidney function.
You have high levels of potassium in your blood (a condition called hyperkalemia).
You are currently experiencing or recently had a heart attack or severe chest pain episode (acute coronary syndrome).
You are pregnant.
Your heart's pumping strength is significantly reduced — specifically, if the main pumping chamber of your heart is working at less than 40% of its normal capacity.
You are currently taking a medication called eplerenone.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Assiut University

Registry

ClinicalTrials.gov

Start date

10 August 2024

Est. completion

13 August 2024

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

AF recurrence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov